Table 3.

Risk of Coronary Heart Disease Death Associated with Silent and Clinically Manifest Myocardial Infarction by Sex and Race.

	Events/1000 person years	Model 1* HR (95% CI)	Model 2† HR (95% CI)	Interaction p-value††
All Population				N/A
No MI (n=8,795)	0.7	1 (ref.)	1 (ref.)
Silent MI (n=317)	3.2	4.10 (2.57–6.53)	3.06 (1.88–4.99)
Clinical MI (n=386)	5.5	6.85 (4.78–9.79)	4.74 (3.26–6.90)
Men				0.089
No MI (n=3,641)	1.0	1 (ref.)	1 (ref.)
Silent MI (n=178)	3.6	3.23 (1.79–5.81)	2.77 (1.51–5.10)
Clinical MI (n=279)	5.5	5.49 (3.61–8.34)	4.39 (2.83–6.63)
Women
No MI (n=5,154)	0.4	1 (ref.)	1 (ref.)
Silent MI (n=139)	2.8	6.92 (3.26–14.7)	3.79 (1.65–8.73)
Clinical MI (n=107)	5.5	12.7 (6.66–24.0)	5.67 (2.78–11.6)
White				0.204
No MI (n=6,993)	0.5	1 (ref.)	1 (ref.)
Silent MI (n=243)	2.6	4.01 (2.23–7.24)	3.30 (1.82–6.01)
Clinical MI (n=332)	4.6	6.60 (4.31–10.1)	4.52 (2.92–6.99)
Black
No MI (n=1,802)	1.1	1 (ref.)	1 (ref.)
Silent MI (n=74)	5.4	4.15 (1.93–8.89)	2.62 (1.06–6.48)
Clinical MI (n=54)	11.5	7.22 (3.75–13.9)	5.57 (2.60–11.9)

HR=hazard ratio; CI=confidence interval; MI= myocardial infarction

^*Model 1 adjusted for age, sex, and race.

^†Model 2 adjusted for variables in model 1 plus study field center, body mass index, education, smoking status, systolic blood pressure, blood pressure lowering medications, diabetes mellitus, ratio of total cholesterol/high density lipoprotein, use of cholesterol lowering medications, use of aspirin, family history of coronary heart disease and serum creatinine (all at baseline).

^††Interactions tested in Model 2.